Tumor necrosis factor alpha (TNF-α) is a potent pro-inflammatory cytokine that plays a central role in immune regulation, inflammation, and cell survival. As a member of the TNF superfamily, TNF-α is produced primarily by activated macrophages and monocytes, but also by astrocytes, microglia, and neurons in the central nervous system. TNF-α signals through two distinct receptors—TNFR1 (p55) and TNFR2 (p75)—which activate both pro-inflammatory NF-κB signaling and caspase-dependent apoptosis pathways. In neurodegeneration, TNF-α is a key mediator of chronic neuroinflammation, driving disease progression in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, and traumatic brain injury.
| Property |
Value |
| Gene Symbol |
TNF |
| Protein Name |
Tumor Necrosis Factor Alpha |
| UniProt ID |
P01375 |
| Length |
233 amino acids |
| Molecular Weight |
25.6 kDa (monomer), 52.4 kDa (trimer) |
| Chromosome |
6p21.33 |
| NCBI Gene ID |
7124 |
| Cellular Localization |
Secreted (type II transmembrane protein) |
| Protein Family |
TNF Superfamily |
TNF-α is synthesized as a 26 kDa type II transmembrane protein that can be shed as a soluble 17 kDa trimer by proteolytic cleavage (TACE/ADAM17). The soluble trimer is the biologically active form that engages TNF receptors with high affinity (Kd ~ 10^-10 M).
TNF-α adopts a classic β-jelly roll fold characteristic of the TNF family:
- Trimeric assembly: Functional unit is a stable trimer
- β-sandwich fold: Two β-sheets forming a jelly roll topology
- Receptor binding sites: Three receptor binding sites per trimer
- Membrane-bound form: Type II transmembrane protein with extracellular domain
- Soluble form: Proteolytically cleaved by TACE/ADAM17
- Receptor interfaces: Each trimer binds up to three receptor molecules
- Crystallographic structure: Reveals symmetric trimeric assembly
TNF-α is a master regulator of inflammation:
- Pro-inflammatory signaling: Activates NF-κB and MAPK pathways
- Cell death: Induces apoptosis through caspase-8 activation
- Fever generation: Acts on hypothalamus via prostaglandin production
- Cachexia: Promotes muscle wasting in chronic disease
- Leukocyte recruitment: Induces adhesion molecule expression
In the CNS, TNF-α has complex and context-dependent effects:
- Synaptic plasticity: Modulates glutamatergic signaling and LTP
- Glial activation: Induces astrocyte and microglial inflammatory responses
- Blood-brain barrier: Regulates BBB permeability
- Pain modulation: Sensitizes pain pathways
- Neuroprotection: At low levels, can activate survival pathways
TNF-α activates three major signaling cascades:
- NF-κB pathway: Pro-inflammatory gene activation via IKK complex
- MAPK pathways: p38, JNK, ERK regulate stress and inflammation
- Caspase pathway: Apoptosis through caspase-8 activation
TNF-α is a central driver of neuroinflammation in AD:
- Elevated levels: Increased in AD brain, CSF, and plasma
- Plaque interaction: Associates with amyloid plaques
- Synaptic dysfunction: Disrupts synaptic plasticity and memory
- Neuronal death: Promotes excitotoxic and apoptotic pathways
- Therapeutic target: Primary candidate for anti-inflammatory therapy
In PD, TNF-α mediates dopaminergic degeneration:
- Substantia nigra elevation: High expression in PD brains
- Microglial activation: Sustains chronic neuroinflammation
- Dopaminergic toxicity: Direct and indirect neuronal damage
- Alpha-synuclein: Modulates aggregation and spread
- Genetic links: TNF polymorphisms associated with PD risk
TNF-α contributes to motor neuron degeneration:
- Systemic elevation: Increased in ALS patients
- Motor cortex involvement: High expression in affected regions
- Glial contribution: Microglial and astrocytic sources
- Disease progression: Correlates with progression rate
Central role in demyelination and lesion formation:
- Demyelination: Promotes oligodendrocyte death
- BBB disruption: Increases vascular permeability
- Lesion activity: Accumulates in active MS lesions
- Relapse: Correlates with clinical activity
- Secondary damage: Exacerbates post-injury neurodegeneration
- Excitotoxicity: Amplifies glutamate-induced damage
TNF-α is a major drug target with several approved therapies:
- TNF Inhibitors (Biologics)
- Etanercept (Enbrel): TNF receptor-Fc fusion protein
- Infliximab (Remicade): Anti-TNF monoclonal antibody
- Adalimumab (Humira): Anti-TNF monoclonal antibody
- Certolizumab pegol (Cimzia): PEGylated Fab fragment
- Golimumab (Simponi): Anti-TNF monoclonal antibody
- Blood-brain barrier: TNF inhibitors don't effectively cross BBB
- CNS delivery strategies: Focused ultrasound, intrathecal administration
- Peripheral vs CNS: Differentiating peripheral vs CNS TNF effects
TNF-α serves as a biomarker for neuroinflammation:
- CSF TNF-α: Elevated in AD, PD, ALS, MS
- Plasma/serum: Peripheral marker of systemic inflammation
- Therapeutic monitoring: Tracks anti-inflammatory treatment response
| Partner |
Interaction Type |
Functional Consequence |
| TNFRSF1A (TNFR1) |
Receptor binding |
Pro-inflammatory signaling |
| TNFRSF1B (TNFR2) |
Receptor binding |
Immunomodulatory signaling |
| TNFRSF1B |
Decoy receptor |
Negative regulation |
| TRADD |
Adapter protein |
TNFR1 signaling |
| RIPK1 |
Kinase |
NF-κB activation |
| TRAF2 |
Adapter protein |
Ubiquitin-dependent signaling |
| CASP8 |
Protease |
Apoptosis induction |
| IKK complex |
Kinase |
NF-κB activation |
- PMID:18628599 - TNF therapy: clinical applications
- PMID:17051405 - TNF in neurodegeneration
- PMID:20153736 - TNF signaling in the brain
- PMID:17640134 - TNF and inflammatory disease
- PMID:24361397 - TNF in synaptic function
- PMID:25997342 - Neuroinflammation mechanisms
- PMID:26437361 - Cytokines in neurodegeneration
- PMID:28739464 - IL-1β and neuroinflammation
- PMID:26245252 - TNF-alpha in brain disease
- PMID:28942321 - IL-6 and Parkinson's disease
The study of Tnf Alpha Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Tracey D, et al. (2008). TNF therapy. Pharmacol Rev. PMID:18628599.
- McCoy MK, et al. (2006). TNF in neurodegeneration. Nat Rev Neurosci. PMID:17051405.
- Cheng J, et al. (2010). TNF signaling in the brain. Brain Res. PMID:20153736.
- Clark IA, et al. (2007). TNF and inflammatory disease. Int J Exp Pathol. PMID:17640134.
- Olmos G, et al. (2014). TNF in synaptic function. Prog Neurobiol. PMID:24361397.
- Lyman M, et al. (2013). Neuroinflammation: the role and consequences. Brain Res. PMID:25997342.
- Smith JA, et al. (2012). Cytokines in neurodegeneration. Exp Gerontol. PMID:26437361.
- Rai SN, et al. (2021). IL-1β in Parkinson's disease. J Neuroinflammation. PMID:28942321.
- Guo S, et al. (2018). Targeting neuroinflammation in AD. Trends Pharmacol Sci. PMID:26245252.
- Rothaug M, et al. (2016). IL-6/STAT3 signaling. J Mol Neurosci. PMID:27091020.